The Indian generics and biosimilars manufacturing industry, which accounts for about half of the global generics supply to the US, is concerned about US President Donald Trump’s intention to impose tariffs of “25% or higher” on pharmaceutical, automobile and semiconductor imports.
Multiple media reports have Trump stating that sectoral import tariffs on pharmaceuticals would start at that level, rising substantially over...